Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (Bronx)
AstraZeneca Vaccine: Study of AZD1222 for the Prevention of COVID-19 in Adults (Bronx)
Sponsor:AstraZeneca
Enrolling:Male and Female Patients
Study Length:24 Months
Clinic Visits:7
Minimum Age:18 years old
IRB Number:AAAT2402
U.S. Government ID:NCT04516746
Contact: Logan Posey: 347-590-7280 / lp2907@cumc.columbia.edu
Additional Study Information:

The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.

Do You Qualify?
Are you 18 years old or older?YesNo
Have you ever tested positive for Sars-Co-V-2 (Covid-19)?YesNo
Are you currently pregnant? If N/A select No.YesNo
Are you preventing pregnancy (i.e. birth control)? If N/A select Yes.YesNo
Are you willing to travel to the South Bronx for participation in this study?YesNo
Submit
Cancel
Investigator
Jessica Justman, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Logan Posey
Email: lp2907@cumc.columbia.edu
Phone: 347-590-7280